当前位置: X-MOL 学术Am. J. Transplant. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients
American Journal of Transplantation ( IF 8.9 ) Pub Date : 2022-07-23 , DOI: 10.1111/ajt.17158
Sunjae Bae 1, 2 , Jennifer L Alejo 3 , Teresa P Y Chiang 3 , William A Werbel 4 , Aaron A R Tobian 5 , Linda W Moore 6, 7 , Ashrith Guha 7, 8 , Howard J Huang 7, 9 , Richard J Knight 6, 7 , A Osama Gaber 6, 7 , R Mark Ghobrial 6, 7 , Mara A McAdams-DeMarco 1, 2 , Dorry L Segev 1, 2
Affiliation  

A recent study concluded that SARS-CoV-2 mRNA vaccine responses were improved among transplant patients taking mTOR inhibitors (mTORi). This could have profound implications for vaccine strategies in transplant patients; however, limitations in the study design raise concerns about the conclusions. To address this issue more robustly, in a large cohort with appropriate adjustment for confounders, we conducted various regression- and machine learning-based analyses to compare antibody responses by immunosuppressive agents in a national cohort (n = 1037). MMF was associated with significantly lower odds of positive antibody response (aOR = 0.090.130.18). Consistent with the recent mTORi study, the odds tended to be higher with mTORi (aOR = 1.001.452.13); however, importantly, this seemingly protective tendency disappeared (aOR = 0.470.731.12) after adjusting for MMF. We repeated this comparison by combinations of immunosuppression agents. Compared to MMF + tacrolimus, MMF-free regimens were associated with higher odds of positive antibody response (aOR = 2.394.267.92 for mTORi+tacrolimus; 2.345.5415.32 for mTORi-only; and 6.7810.2515.93 for tacrolimus-only), whereas MMF-including regimens were not, regardless of mTORi use (aOR = 0.811.542.98 for MMF + mTORi; and 0.811.512.87 for MMF-only). We repeated these analyses in an independent cohort (n = 512) and found similar results. Our study demonstrates that the recently reported findings were confounded by MMF, and that mTORi is not independently associated with improved vaccine responses.

中文翻译:


mTOR 抑制剂、霉酚酸酯和其他免疫抑制方案对实体器官移植受者 SARS-CoV-2 mRNA 疫苗抗体反应的影响



最近的一项研究得出结论,服用 mTOR 抑制剂 (mTORi) 的移植患者的 SARS-CoV-2 mRNA 疫苗反应得到改善。这可能对移植患者的疫苗策略产生深远的影响;然而,研究设计的局限性引起了人们对结论的担忧。为了更强有力地解决这个问题,在对混杂因素进行适当调整的大型队列中,我们进行了各种基于回归和机器学习的分析,以比较全国队列中免疫抑制剂的抗体反应( n = 1037)。 MMF 与抗体阳性反应的几率显着降低相关 (aOR = 0.09 0.13 0.18 )。与最近的 mTORi 研究一致,mTORi 的几率往往更高 (aOR = 1.00 1.45 2.13 );然而,重要的是,在调整 MMF 后,这种看似保护性的趋势消失了 (aOR = 0.47 0.73 1.12 )。我们通过免疫抑制剂的组合重复了这种比较。与 MMF + 他克莫司相比,无 MMF 方案与较高的阳性抗体反应几率相关(mTORi+他克莫司的 aOR = 2.39 4.26 7.92 ;仅 mTORi 的aOR = 2.34 5.54 15.32 ;仅他克莫司的 aOR = 6.78 10.25 15.93 ),而 MMF -无论是否使用 mTORi,包括方案都不是(MMF + mTORi 的 aOR = 0.81 1.54 2.98 ;仅 MMF 的 aOR = 0.81 1.51 2.87 )。我们在一个独立队列 ( n = 512) 中重复了这些分析,并发现了类似的结果。 我们的研究表明,最近报告的发现与 MMF 相混淆,并且 mTORi 与疫苗反应改善并不独立相关。
更新日期:2022-07-23
down
wechat
bug